News on research and diagnostics for metabolic disorders and metabolic diseases.
Bio-Techne expects the acquisition will provide it with a basis to build out its IVD presence, given Asuragen's diagnostic tests and regulatory expertise.
For the three months ended Dec. 31, 2020, the firm reported $400,000 in pharmaceutical service revenue compared to none in 2019.
RenalytixAI will provide financial support to the University of Utah in the form of sponsored research into kidney disease progression, treatment, and biomarkers.
The consortium, recently funded with €750,000, is developing a computational tool for identifying NAFLD patients at high risk of progressing to NASH.
Weill Cornell Medicine, New York-Presbyterian Hospital, and the New York Genome Center will join Illumina to sequence the genomes of thousands of patients.
